Cultural Heritage
The Top 100 Chinese Traditional Medicine Enterprises List Has Been Released—Qizheng Tibetan Medicine Appears on the List Again!
Release time:
2022-07-15 13:20
Recently, the "Top 100 Chinese Traditional Chinese Medicine Enterprises Ranking" was released, and Qizheng Tibetan Medicine (002287) was honorably listed at No. 32, jumping 10 places ahead of last year's ranking.
This ranking was released by the Expert Committee of the Top 100 Chinese Pharmaceutical Industry List compiled by the Minne Research Institute. It is reported that this evaluation, based on a database covering the three major terminals and six key market segments, scores companies from two primary dimensions—“the enterprise’s innovation-driven force” and “the enterprise’s professional promotion capability”—in a scientifically rigorous manner. As a result, it has attracted extensive attention and active participation from specialized research institutions, industry experts and scholars, entrepreneurs, and peers in the sector, exerting a significant impact.
Qizheng Tibetan Medicine is a leading Chinese enterprise in the Tibetan medicine industry, primarily engaged in the research and development, production, and sales of innovative Tibetan medicines. The company holds 25 exclusive product varieties and 141 approved drug registration numbers, with its products covering areas such as the musculoskeletal system, nervous system, digestive system, cardiovascular and cerebrovascular system, respiratory system, urinary system, gynecology, dermatology, and pediatrics.
Qizheng Tibetan Medicine takes it upon itself to carry forward the millennia-old tradition of Tibetan medicine in a modern context, driving innovation and upgrading of the traditional Tibetan medicine industry through R&D innovation and technological advancement. The company has been recognized as one of the first batch of National Innovative Enterprises, a National High-Tech Enterprise, a National Demonstration Enterprise for Technological Innovation, a Key High-Tech Enterprise under the National Torch Program, and a National Enterprise Technology Center. It also operates two national-local joint laboratories and has successively undertaken key projects under the National “11th Five-Year” Science and Technology Support Plan, as well as major science and technology programs during the “12th Five-Year” and “13th Five-Year” periods.
The company’s operations are centered on patient needs. Leveraging the unique clinical value and differentiated therapeutic advantages of Tibetan medicine, we provide patients with excellent treatment options and a superior clinical experience, earning high recognition from both clinicians and patients. Our brand has been repeatedly listed among “China’s Top Brands for Household Essential Medicines.” In 2021, our initiative “Qingpeng Digital Marketing Precisely Reaches Out to Gout Patients” was honored with accolades such as “Top Ten Marketing Cases in China’s Pharmaceutical Industry 2021.”
In 2021, Qizheng Tibetan Medicine achieved an operating revenue of 1.77 billion yuan, representing a year-on-year increase of 19.22%; net profit attributable to shareholders of the listed company reached 716 million yuan, up 77.21% from the same period last year. During this year, the company acquired Tibet Tibetan Medicine Group Co., Ltd.; the marketing authorization holder for the 59 drug approvals held by Sanpu Pharmaceutical, which was also acquired, was successfully changed, significantly enriching the company’s product portfolio and laying a solid foundation for the sustainable development of Qizheng’s product lineup. Additionally, the company acquired Lintao Qizheng Tibetan Hospital and took a stake in Guangdong Baiyuantang Pharmaceutical Chain Co., Ltd., taking a firm step toward integrating into the entire pharmaceutical industry chain. Furthermore, the company was recognized by China’s Ministry of Industry and Information Technology as a “National Demonstration Enterprise for Technological Innovation.”
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO